BVS
BioventusBNasdaq / Health Care Equipment & Services
Last Price
At close
2026-06-02
Current thesis
Q1 showed broad-based revenue growth across all three segments, cash generation improved sharply, and management raised 2026 Adjusted EPS and cash-from-operations guidance. Reimbursement noise around Exogen also looks de-risked for FY2026, which can support a modest rerating if execution persists.
Posture
Constructive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta +1.3.
What can break
Execution on margin expansion, cash flow conversion, and deleveraging has to continue for the rerating case to hold.
Momentum
46
Value
64
Sentiment
62
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $10.25 · Bull $15.00 · Bear $6.25
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-29 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $14.50
Why
Momentum46 · Δ7d -36.1
Value64 · Δ7d +1.3
Sentiment62 · Δ7d +13.6
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Value · See fundamentals
Momentum
46
34% active weight
Current posture
7d trendSoftening
Δ7d
-36.1
Δ21d
-41.1
Value
64
32% active weight
Current posture
7d trendImproving
Δ7d
+1.3
Δ21d
+2.4
Sentiment
62
33% active weight
Current posture
7d trendImproving
Δ7d
+13.6
Δ21d
+13.6
Why this grade
Composite grade B. Momentum 45.6 / Value 63.7 / Sentiment 61.5
Fundamentals (TTM)As of 2026-06-01
Fundamentals (TTM)
As of 2026-06-01
Market Cap
$662.43M
Beta
0.79
Shares Out
82.76M
P/E (TTM)
67.4
P/S (TTM)
1.11
P/FCF (TTM)
11.72
Rev YoY
-0.2%
EPS YoY
+157.9%
Gross Margin
+67.8%
Op Margin
+7.5%
Net Debt
$304.43M
Current Ratio
1.74
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology